Jefferies believes cancer-screening company Freenome is on the verge of a major growth phase, initiating coverage this week with a buy rating and a $17 price target — implying roughly 47% upside from Friday’s closing price. The call comes as Freenome prepares to broadly commercialize its diagnostic services this fall, a milestone analyst Tycho Peterson says could unlock significant value for shareholders after years of clinical development. “We see FRNM as uniquely positioned from a development and commercial standpoint, with a multi-year penetration ramp ahead,” Peterson wrote in his note initiating coverage.
Peterson pointed to several near-term catalysts, including royalty streams, development milestones, and expansion into new diagnostic indications. Freenome currently focuses on colorectal cancer detection but is expected to broaden into lung and other cancer screenings, a move Jefferies says could meaningfully widen its addressable market over the next several years. Reimbursement is another key driver behind the bullish case: the company has already secured American Cancer Society guideline inclusion for colorectal screening, and Jefferies expects potential commercial insurance coverage even before a broader U.S. Preventive Services Task Force review, which isn’t expected until late 2027 or 2028. Shares have already climbed 12% over the past three months and jumped more than 7% on the day of the Jefferies call, showing the market is starting to price in the upcoming catalysts.
This is a higher-risk, higher-reward name for investors willing to take on clinical-stage healthcare volatility in exchange for exposure to a potential first-mover in blood-based cancer diagnostics. The fall commercialization launch is the catalyst to watch closely — if reimbursement coverage expands as Jefferies expects, revenue growth could accelerate quickly from a small base. Investors should treat this as a speculative healthcare position rather than a core portfolio holding, sized accordingly given the binary nature of diagnostic-company catalysts, but it’s a name worth tracking for anyone looking to diversify beyond mega-cap AI stocks into early-stage medical innovation with real near-term commercial milestones.
